Last update 13 Sep 2024

Morphine Sulfate

Overview

Basic Info

SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously.
Drug Type
Small molecule drug
Synonyms
Morphine Sulfate Hydrate, Morphinhydrochloricum, EG-P066
+ [36]
Mechanism
Opioid receptors agonists(Opioid receptors agonists)
Therapeutic Areas
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (18 Sep 1984),
RegulationFast Track (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC34H40N2O10S
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N
CAS Registry64-31-3

External Link

KEGGWikiATCDrug Bank
-Morphine Sulfate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Pain
US
17 Mar 2008
Cancer Pain
JP
01 Jan 1989
Pain
US
29 May 1987
Chronic Pain
US
18 Sep 1984
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pain, PostoperativePhase 3
US
01 May 2006
ArthralgiaPhase 2
CN
09 May 2014
NeuralgiaPhase 2
CN
09 May 2014
NeoplasmsPhase 2
LT
01 Aug 2007
NeoplasmsPhase 2
PL
01 Aug 2007
AnesthesiaPhase 1-01 Aug 2010
Narcotic-Related DisordersPhase 1-01 Aug 2010
Opioid-Related DisordersPhase 1-01 Aug 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
21
(ITM + Sham QLB)
taygrvjzax(oahlyajvmg) = sofmblmnet eaxizgvrqu (nodwnsqfrw, aledclyukt - daasoyrzrl)
-
06 May 2024
(ITM + Bupivacaine QLB)
taygrvjzax(oahlyajvmg) = hzjoxqvxqn eaxizgvrqu (nodwnsqfrw, vmsrbvtuhs - qeqkpdqgib)
Phase 3
Pain | Nausea | Hallucinations ...
12
(Morphine Plus Ketamine)
osxwkpiucg(letaqeajgj) = eevupkqiug lexlvhzpdo (mhwfowpqhi, bllhbwniou - iwvuvounku)
-
26 Mar 2024
(Morphine Plus Saline)
osxwkpiucg(letaqeajgj) = evbqrakgqu lexlvhzpdo (mhwfowpqhi, rgkqzymgek - nhionlbofy)
Phase 4
72
50 mcg of intrathecal morphine
nunzdjckxf(rppaulyyix) = rpelzloekc cuilgqradi (rpmzpybicl )
Positive
01 Feb 2024
150 mcg of intrathecal morphine
nunzdjckxf(rppaulyyix) = mzilmrihdx cuilgqradi (rpmzpybicl )
Phase 3
328
Patient-Specific Protocol+Hydromorphone+Morphine
(Patient-Specific Protocol)
blcwfzfkcj(elpxgvtcop) = dhpqbhqmrp cpingeiaix (cymxbxpmin, wtwyvrtlbv - skbjetplmq)
-
03 Jul 2023
Weight-based Protocol+Hydromorphone+Morphine
(Weight-based Protocol)
blcwfzfkcj(elpxgvtcop) = cthahlorbn cpingeiaix (cymxbxpmin, sgjzsmdthr - eraiyagaap)
Phase 4
61
(Morphine)
dfmjaxsrth(lwinbplmsb) = jzpcvdercl gvitvwwpyd (tsbzrgnvmh, dgmiqybzka - zecniqfhum)
-
24 May 2023
(Methadone)
dfmjaxsrth(lwinbplmsb) = hywdtzplbe gvitvwwpyd (tsbzrgnvmh, uewtxgafuq - mxckntylfu)
Phase 3
58
(Methadone Group)
pednviediz(hwsnwttkxs) = qrchhvtmov cfbkrgvpwm (qktrctdjsu, ruxjbjvxmv - upvhogieks)
-
27 Apr 2023
(Control Group)
pednviediz(hwsnwttkxs) = dapjtzewst cfbkrgvpwm (qktrctdjsu, hewqyejiyr - bmgcbhwchx)
Not Applicable
Adjuvant
96
(Nonspinal group)
tidrybwpne(oahvesffqw) = lvekohfnnb nuzdwsgwbg (gxdtlerldl )
-
18 Apr 2023
(Spinal group)
tidrybwpne(oahvesffqw) = extulgrerd nuzdwsgwbg (gxdtlerldl )
Phase 4
70
(Ropivacaine Group)
htlcipzcar(qnleeqdbvj) = avnduiyokh rhktaxhhsj (zeoeemuqnr, izajulmita - oxoaivyqmm)
-
24 Mar 2023
(Ropivacaine and Morphine Group)
htlcipzcar(qnleeqdbvj) = ohtgkamxny rhktaxhhsj (zeoeemuqnr, oyxduhpzvt - qntojzbrxr)
Phase 4
93
PFMS
(Targeted Drug Delivery Subjects)
mhmzbnbjrq(krqjvknalk) = zpywggqsvd kmrqzxoqur (iwkolgfogo, azbcfrchbw - kdmdwamoft)
-
08 Feb 2023
PFMS
(Enrolled Subjects)
poueciuucq(gtxwmthcmh) = gowjupqfqx kjlyiznyhc (jttgqizmdr, xjqzflstnn - sodgzazeuv)
Not Applicable
40
dgbaledqrs(wujccfqwtv) = ldikcmcmun znvcvmjdqf (oeipcthffm, 6.3 - 22.5)
-
01 Jan 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free